ArQule To Report Second Quarter 2017 Financial Results On August 4, 2017
July 21 2017 - 7:00AM
Business Wire
ArQule, Inc. (Nasdaq: ARQL) today announced it will report
financial results for the second quarter 2017 before the market
opens on Friday, August 4, 2017. The Company will hold a conference
call and webcast on the same day at 9:00 a.m. ET to discuss these
results and provide a general business update.
The live webcast can be accessed in the “Investors and Media”
section of our website, www.arqule.com, under “Events &
Presentations.” You may also listen to the call by dialing (877)
868-1831 within the U.S. or (914) 495-8595 outside the U.S. A
replay will be available two hours after the completion of the call
and can be accessed in the “Investors & Media” section of our
website, www.arqule.com, under “Events and Presentations.”
About ArQule
ArQule is a biopharmaceutical company engaged in the research
and development of targeted therapeutics to treat cancers and rare
diseases. ArQule’s mission is to discover, develop and
commercialize novel small molecule drugs in areas of high unmet
need that will dramatically extend and improve the lives of our
patients. Our clinical-stage pipeline consists of five drug
candidates, all of which are in targeted, biomarker-defined patient
populations, making ArQule a leader among companies our size in
precision medicine. ArQule’s proprietary pipeline includes: ARQ
087, a multi-kinase inhibitor designed to preferentially inhibit
the fibroblast growth factor receptor (FGFR) family, in phase 2 for
iCCA and in phase 1b for multiple oncology indications; ARQ 092, a
selective inhibitor of the AKT serine/threonine kinase, in a phase
1/2 company sponsored study for Overgrowth Diseases, in a phase 1
study for ultra-rare Proteus syndrome conducted by the National
Institutes of Health (NIH), as well as in multiple oncology
indications; ARQ 751, a next generation AKT inhibitor, in phase 1
for patients with AKT1 and PI3K mutations; and ARQ 761, a
β-lapachone analog being evaluated as a promoter of NQO1-mediated
programmed cancer cell necrosis, in phase 1/2 in multiple oncology
indications in partnership with the University of Texas
Southwestern Medical Center. In addition, we have advanced ARQ 531,
an investigational, orally bioavailable, potent and reversible
inhibitor of both wild type and C481S-mutant BTK, in phase 1 for
patients with B-cell malignancies refractory to other therapeutic
options. ArQule’s current discovery efforts are focused on the
identification and development of novel kinase inhibitors,
leveraging the Company’s proprietary library of compounds. You can
follow us on Twitter and LinkedIn.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170721005029/en/
ArQule, Inc.Dawn Schottlandt, 781-994-0300Vice President,
Investor Relations/ Corp. Communicationswww.arqule.com
ArQule (NASDAQ:ARQL)
Historical Stock Chart
From Apr 2024 to May 2024
ArQule (NASDAQ:ARQL)
Historical Stock Chart
From May 2023 to May 2024